Related Experiment Videos

Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and

T Iizumi1, T Yazaki, M Waku

  • 1Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.

The Journal of Urology
|August 1, 1989
PubMed

Insights

Recombinant human tumor necrosis factor (rTNF-S) effectively inhibited murine bladder tumor growth. Combining rTNF-S with etoposide or hyperthermia further enhanced its antitumor effects, suggesting potential for human bladder cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Tumor necrosis factor (TNF) is a cytokine with known antitumor properties.
  • TNF exhibits species-specific activity, necessitating investigation into human TNF efficacy for human tumors.
  • Murine bladder tumor (MBT-2) models are used to study bladder cancer progression and treatment responses.

Purpose of the Study:

  • To evaluate the efficacy of a novel recombinant human tumor necrosis factor (rTNF-S) against murine bladder tumors.
  • To determine if combination therapies involving rTNF-S, etoposide, and/or hyperthermia can enhance antitumor effects.
  • To assess the potential clinical relevance of human TNF for treating human bladder cancer.

Main Methods:

  • Intratumor injection of rTNF-S into established murine bladder tumors (MBT-2).
  • Administration of etoposide (VP-16) and/or hyperthermia in conjunction with rTNF-S.
  • Monitoring and quantification of tumor growth inhibition and response to treatments.

Main Results:

  • Intratumor injection of rTNF-S significantly inhibited the growth of MBT-2 tumors.
  • Combination of rTNF-S with etoposide demonstrated an enhanced antitumor effect.
  • Co-administration of rTNF-S with hyperthermia (at low temperatures) also potentiated the inhibition of tumor growth.
  • The observed effects suggest a promising therapeutic window for rTNF-S in bladder cancer treatment.

Conclusions:

  • Recombinant human tumor necrosis factor (rTNF-S) exhibits significant direct antitumor activity against murine bladder tumors.
  • Combination strategies using rTNF-S with conventional agents like etoposide or physical methods like hyperthermia can augment therapeutic outcomes.
  • These findings support the potential application of human TNF-based therapies for human bladder cancer, considering TNF's species specificity.

Related Concept Videos